ARTICLE | Clinical News
Chronogesic sufentanil: Began Phase III trial
November 5, 2001 8:00 AM UTC
Durect Corp. (DRRX), Cupertino, Calif. Product: Chronogesic sufentanil (formerly Duros) Business: Neurological Therapeutic category: Analgesic Target: Opioid receptors Description: Subcutaneous imp...